Fibrinogen-like protein 2/fibroleukin induces long-term allograft survival in a rat model through regulatory B cells

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Bézie, Séverine ^a   Picarda, Elodie ^a   Tesson, Laurent ^a   Renaudin, Karine ^a   Durand, Justine ^a   Ménoret, Séverine ^a   Mérieau, Emmanuel ^a   Chiffoleau, Elise ^a   Guillonneau, Carole ^a   Caron, Lise ^a   Anegon, Ignacio ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; CELL PROTEIN; FIBRINOGEN LIKE PROTEIN 2; FIBROLEUKIN; UNCLASSIFIED DRUG; FIBRINOGEN; FIBRINOGEN-LIKE PROTEIN 2, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CELL LEVEL; CELL TRANSFER; CONTROLLED STUDY; DISEASE MARKER; GENE TRANSFER; GRAFT SURVIVAL; HEART GRAFT; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTE SUBPOPULATION; MALE; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; ALLOGRAFT; ANIMAL; GENETICS; GRAFT REJECTION; METABOLISM; TRANSPLANTATION;

ADENOVIRIDAE; ANIMALIA; RATTUS;

ALLOGRAFTS; ANIMALS; B-LYMPHOCYTES, REGULATORY; FIBRINOGEN; GENE TRANSFER TECHNIQUES; GRAFT REJECTION; GRAFT SURVIVAL; MALE; RATS;

EID: 84928914740     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119686     Document Type: Article

References (49)

1. Guillot C, Guillonneau C, Mathieu P, Gerdes CA, Ménoret S, Braudeau C, et al. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. J Immunol. 2002;168:1600-1609. PMID: 11823487
2. Guillonneau C, Hill M, Hubert F-X, Chiffoleau E, Hervé C, Li X-L, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2, 3-dioxygenase. J Clin Invest. 2007;117:1096-1106. doi: 10.1172/JCI28801 PMID: 17404623
3. Picarda E, Bézie S, Venturi V, Echasserieau K, Mérieau E, Delhumeau A, et al. MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection. J Clin Invest. 2014; doi: 10. 1172/JCI71533
4. Guillonneau C, Picarda E, Anegon I. CD8+ regulatory T cells in solid organ transplantation. Curr Opin Organ Transplant. 2010; doi: 10.1097/MOT.0b013e32834016d1
5. Li XL, Ménoret S, Bezie S, Caron L, Chabannes D, Hill M, et al. Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance. J Immunol. 2010;185:823-833. doi: 10.4049/jimmunol.1000120 PMID: 20543104
6. Ning Q, Sun Y, Han M, Zhang L, Zhu C, Zhang W, et al. Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection. J Immunol. 2005;174:7403-7411. PMID: 15905589
7. Ghanekar A, Mendicino M, Liu H, He W, Liu M, Zhong R, et al. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol. 2004;172:5693-5701. PMID: 15100314
8. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6:1142-1151. doi: 10.1038/ni1263 PMID: 16227984
9. Shalev I, Wong KM, Foerster K, Zhu Y, Chan C, Maknojia A, et al. The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology. 2009;49:387-397. doi: 10.1002/hep. 22684 PMID: 19085958
10. Foerster K, Helmy A, Zhu Y, Khattar R, Adeyi OA, Wong KM, et al. The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection. J Hepatol. 2010;53:608-615. doi: 10.1016/j.jhep. 2010.04.020 PMID: 20615566
11. Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40:569-581. doi: 10.1016/j.immuni.2014.02.012 PMID: 24745333
12. Liu H, Shalev I, Manuel J, He W, Leung E, Crookshank J, et al. The FGL2-FcgammaRIIB pathway: a novel mechanism leading to immunosuppression. Eur J Immunol. 2008;38:3114-3126. doi: 10.1002/eji.200838338 PMID: 18991288
13. Picarda E, Anegon I, Guillonneau C. T-cell receptor specificity of CD8 (+) Tregs in allotransplantation. Immunotherapy. 2011;3:35-37. doi: 10.2217/imt.11.37 PMID: 21524168
14. Mauri C, Ehrenstein MR. The "short" history of regulatory B cells. Trends Immunol. 2008;29:34-40. doi: 10.1016/j.it.2007.10.004 PMID: 18289504
15. Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. Immunol Rev. 2011;241:206-227. doi: 10.1111/j.1600-065X.2011.01015.x PMID: 21488899
16. Ménoret S, Iscache A-L, Tesson L, Rémy S, Usal C, Osborn MJ, et al. Characterization of immunoglobulin heavy chain knockout rats. Eur J Immunol. 2010;40:2932-2941. doi: 10.1002/eji.201040939 PMID: 21038471
17. Anjubault T, Martin J, Hubert F-X, Chauvin C, Heymann D, Josien R. Constitutive expression of TNF-related activation-induced cytokine (TRANCE)/receptor activating NF-κB ligand (RANK)-L by rat plasmacytoid dendritic cells. PLoS ONE. 2012;7:e33713. doi: 10.1371/journal.pone.0033713 PMID: 22428075
18. Toromanoff A, Chérel Y, Guilbaud M, Penaud-Budloo M, Snyder RO, Haskins ME, et al. Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther. 2008;16:1291-1299. doi: 10.1038/mt.2008.87 PMID: 18461055
19. Le Guiner C, Stieger K, Snyder RO, Rolling F, Moullier P. Immune responses to gene product of inducible promoters. Curr Gene Ther. 2007;7:334-346. PMID: 17979680
20. Brüggemann M, Teale C, Clark M, Bindon C, Waldmann H. A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha. J Immunol. 1989;142:3145-3150. PMID: 2496159
21. Cuturi MC, Josien R, Cantarovich D, Bugeon L, Anegon I, Menoret S, et al. Decreased anti-donor major histocompatibility complex class I and increased class II alloantibody response in allograft tolerance in adult rats. Eur J Immunol. 1994;24:1627-1631. doi: 10.1002/eji.1830240726 PMID: 8026523
22. Schwartz BS, Levy GA, Fair DS, Edgington TS. Murine lymphoid procoagulant activity induced by bacterial lipopolysaccharide and immune complexes is a monocyte prothrombinase. J Exp Med. 1982;155:1464-1479. PMID: 7200121
23. Chan CWY, Chan MWC, Liu M, Fung L, Cole EH, Leibowitz JL, et al. Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. J Immunol. 2002;168:5170-5177. PMID: 11994472
24. Mendicino M, Liu M, Ghanekar A, He W, Koscik C, Shalev I, et al. Targeted deletion of Fgl-2/fibroleukin in the donor modulates immunologic response and acute vascular rejection in cardiac xenografts. Circulation. 2005;112:248-256. doi: 10.1161/CIRCULATIONAHA.105.534271 PMID: 15998670
25. Marsden PA, Ning Q, Fung LS, Luo X, Chen Y, Mendicino M, et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest. 2003;112:58-66. doi: 10.1172/JCI18114 PMID: 12840059
26. Melnyk MC, Shalev I, Zhang J, Bartczak A, Gorczynski RM, Selzner N, et al. The prothrombinase activity of FGL2 contributes to the pathogenesis of experimental arthritis. Scand J Rheumatol. 2011;40:269-278. doi: 10.3109/03009742.2010.536163 PMID: 21469939
27. Chan CWY, Kay LS, Khadaroo RG, Chan MWC, Lakatoo S, Young KJ, et al. Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. J Immunol. 2003;170:4036-4044. PMID: 12682232
28. Shalev I, Liu H, Koscik C, Bartczak A, Javadi M, Wong KM, et al. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. J Immunol. 2008;180:249-260. PMID: 18097026
29. Xie L, Ichimaru N, Morita M, Chen J, Zhu P, Wang J, et al. Identification of a novel biomarker gene set with sensitivity and specificity for distinguishing between allograft rejection and tolerance. Liver Transpl. 2012;18:444-454. doi: 10.1002/lt.22480 PMID: 22162188
30. Denning TL, Granger SW, Granger S, Mucida D, Graddy R, Leclercq G, et al. Mouse TCRalphabeta +CD8alphaalpha intraepithelial lymphocytes express genes that down-regulate their antigen reactivity and suppress immune responses. J Immunol. 2007;178:4230-4239. PMID: 17371979
31. Hancock WW, Szaba FM, Berggren KN, Parent MA, Mullarky IK, Pearl J, et al. Intact type 1 immunity and immune-associated coagulative responses inmice lacking IFN gamma-inducible fibrinogen-like protein 2. Proc Natl Acad Sci USA. 2004;101:3005-3010. doi: 10.1073/pnas.0308369101 PMID: 14976252
32. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221-241. doi: 10.1146/annurev-immunol-020711-074934 PMID: 22224776
33. Deng S, Moore DJ, Huang X, Lian M-M, Mohiuddin M, Velededeoglu E, et al. Cutting edge: transplant tolerance induced by anti-CD45RB requires B lymphocytes. J Immunol. 2007;178:6028-6032. PMID: 17475825
34. Lee KM, Kim JI, Stott R, Soohoo J, O'Connor MR, Yeh H, et al. Anti-CD45RB/Anti-TIM-1-Induced Tolerance Requires Regulatory B Cells. Am J Transplant. 2012;12:2072-2078. doi: 10.1111/j.1600-6143. 2012.04055.x PMID: 22494812
35. Le Texier L, Thebault P, Lavault A, Usal C, Merieau E, Quillard T, et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant. 2011;11:429-438. doi: 10.1111/j.1600-6143.2010.03336.x PMID: 21114655
36. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010;120:1836-1847. doi: 10.1172/JCI39933 PMID: 20501946
37. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, et al. Development of a crossplatform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest. 2010;120:1848-1861. doi: 10.1172/JCI39922 PMID: 20501943
38. Kendal AR, Waldmann H. Infectious tolerance: therapeutic potential. Curr Opin Immunol. 2010;22:560-565. doi: 10.1016/j.coi.2010.08.002 PMID: 20829013
39. Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, et al. "Infectious" transplantation tolerance. Science. 1993;259:974-977. PMID: 8094901
40. Yanaba K, Bouaziz J-D, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28:639-650. doi: 10.1016/j.immuni.2008.03.017 PMID: 18482568
41. Neves P, Lampropoulou V, Calderon-Gomez E, Roch T, Stervbo U, Shen P, et al. Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during Salmonella typhimurium infection. Immunity. 2010;33:777-790. doi: 10.1016/j.immuni.2010.10.016 PMID: 21093317
42. Pallier A, Hillion S, Danger R, Giral M, Racapé M, Degauque N, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int. 2010;78:503-513. doi: 10.1038/ki.2010.162 PMID: 20531452
43. Wei B, Velazquez P, Turovskaya O, Spricher K, Aranda R, Kronenberg M, et al. Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc Natl Acad Sci USA. 2005;102:2010-2015. doi: 10.1073/pnas.0409449102 PMID: 15684084
44. Blair PA, Chavez-Rueda KA, Evans JG, Shlomchik MJ, Eddaoudi A, Isenberg DA, et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol. 2009;182:3492-3502. doi: 10.4049/jimmunol.0803052 PMID: 19265127
45. Qian L, Qian C, Chen Y, Bai Y, Bao Y, Lu L, et al. Regulatory dendritic cells program B cells to differentiate into CD19hiFcγIIbhi regulatory B cells through IFN-β and CD40L. Blood. 2012;120:581-591. doi: 10.1182/blood-2011-08-377242 PMID: 22692512
46. Matsumoto M, Fujii Y, Baba A, Hikida M, Kurosaki T, Baba Y. The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. Immunity. 2011;34:703-714. doi: 10.1016/j.immuni.2011.03.016 PMID: 21530328
47. Mann MK, Maresz K, Shriver LP, Tan Y, Dittel BN. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol. 2007;178:3447-3456. PMID: 17339439
48. Carter NA, Vasconcellos R, Rosser EC, Tulone C, Muñoz-Suano A, Kamanaka M, et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol. 2011;186:5569-5579. doi: 10.4049/jimmunol.1100284 PMID: 21464089
49. Amu S, Saunders SP, Kronenberg M, Mangan NE, Atzberger A, Fallon PG. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol. 2010;125:1114-1124.e8. doi: 10.1016/j.jaci.2010.01.018 PMID: 20304473